Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
(NasdaqGM:SLGL),(NASDAQ:VTRS), Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug's commercial potential In September 2025, Sol-Gel announced Health Canada approval of EPSOLAY Sol-Gel signed an additional agreement with Viatris covering Australia and New Zealand for both EPSOLAY and TWYNEO […]